Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Financing Activities: 2011-2025

Historic Cash from Financing Activities for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to -$27.8 million.

  • Adma Biologics' Cash from Financing Activities fell 9.26% to -$27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.9 million, marking a year-over-year increase of 0.51%. This contributed to the annual value of -$58.3 million for FY2024, which is 49.53% down from last year.
  • Per Adma Biologics' latest filing, its Cash from Financing Activities stood at -$27.8 million for Q3 2025, which was down 58,068.75% from $48,000 recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Cash from Financing Activities peaked at $62.7 million during Q4 2022, and registered a low of -$39.0 million during Q4 2023.
  • Its 3-year average for Cash from Financing Activities is -$12.0 million, with a median of -$1.4 million in 2024.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 1,014,330.22% in 2021, then tumbled by 6,221.88% in 2024.
  • Adma Biologics' Cash from Financing Activities (Quarterly) stood at $53.8 million in 2021, then grew by 16.58% to $62.7 million in 2022, then slumped by 162.15% to -$39.0 million in 2023, then climbed by 20.44% to -$31.0 million in 2024, then declined by 9.26% to -$27.8 million in 2025.
  • Its last three reported values are -$27.8 million in Q3 2025, $48,000 for Q2 2025, and -$7.1 million during Q1 2025.